Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS In the opinion of management, the accompanying interim financial statements include all the normal and recurring adjustments, which consist primarily of accruals, estimates, and assumptions that impact financial statements, considered necessary to present
EX-99.4 4 tm2622598d1_ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 YARROW BIOSCIENCE, INC. In connection with the closing of the Merger (as defined below in Note 1), Yarrow Bioscience, Inc. changed its name to Yarrow Bioscience Operating Company Corp. on July 27, 2026. For the purposes of these financial statements, references to Yarrow Bioscience, Inc. refer to the company prior to the Merger. INDEX TO FINANCIAL STATEMENTS Page Unaudited Interim Financial Statements Balance Sheets F-2 Statements of Operations F-3 Statement of Convertible Preferred Stock and Stockholders’ Deficit F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 F- 1 YARROW BIOSCIENCE, INC. B alance SheetS (in thousands, except share and per share data) June 30, 2026 December 31, 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $ 18,670 $ 99,994 Restricted cash 105 — Prepaid and other current ass...
Source
Exhibit EX-99.4
0001104659-26-095925
Filed August 13, 2026 at 8:14 PM UTC. The figures above are from the audited statements, not from this release.